Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESET-MDR: Encapsulated fecal microbiota transfer for decolonization of multidrug-resistant Enterobacteriaceae carriers
2024-519748-34-00Phase 2Suspended
- Sponsor
- Goethe University Frankfurt
- Start
- May 2025
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Intestifix and INTESTIFIX 001 in Multidrug-resistant Enterobacteriaceae intestinal colonization (MDREIC) (2 arms), sponsored by Goethe University Frankfurt. Primary endpoint: Detectable intestinal carriage of MDR-E at day 30 (qualitative culture). Started May 2025; status: suspended.
02
Drugs
IntestifixINTESTIFIX 001
03
Conditions
Multidrug-resistant Enterobacteriaceae intestinal colonization (MDREIC)
Beyond the preview
Go deeper on 2024-519748-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519748-34-00.